The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ISCO | +46.67% | -65.48% | -19.15% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +391% |
International Stem Cell Corp. operates as a research and development company for the therapeutic market. It focuses on advancing potential clinical applications of human parthenogenetic stem cells for the treatment of various diseases of the central nervous system and liver diseases. The firm operates through three segments: Therapeutic Market, Biomedical Market and Anti-Aging Market. The Biomedical Market segment markets and sells primary human cell research products with two product categories, cells and media. The Anti-Aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.
No news articles found for International Stem Cell.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.37M | 8.7% |
| Gross Profit | $1.30M | 9.8% |
| Gross Margin | 54.92% | 0.5% |
| Market Cap | $1.04M | 116.7% |
| Market Cap / Employee | $32.52K | 0.0% |
| Employees | 32 | 0.0% |
| Net Income | $29.00K | 123.2% |
| EBITDA | $150.00K | 505.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $966.00K | -26.1% |
| Accounts Receivable | $1.02M | 49.3% |
| Inventory | 1.6 | 15.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $103.00K | -49.3% |
| Short Term Debt | $3.69M | 0.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -2.85% | 10.7% |
| Return On Invested Capital | -68.04% | 10.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $46.00K | -79.1% |
| Operating Free Cash Flow | $49.00K | -80.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.16 | -0.25 | -0.31 | -0.27 | 123.37% |
| Price to Sales | 0.07 | 0.11 | 0.14 | 0.11 | 100.76% |
| Price to Tangible Book Value | -0.14 | -0.21 | -0.26 | -0.23 | 125.97% |
| Price to Free Cash Flow TTM | 1.84 | 5.79 | 3.63 | 35.88 | - |
| Enterprise Value to EBITDA | 72.05 | -49.55 | 38.40 | 54.61 | -127.48% |
| Free Cash Flow Yield | 54.4% | 17.3% | 27.5% | 2.8% | - |
| Return on Equity | -110.1% | -246.4% | -88.1% | -38.1% | -81.88% |
| Total Debt | $3.84M | $4.10M | $3.85M | $3.79M | -2.17% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
